Skip to content
  • Sun. Jun 15th, 2025

Producers Online

Producers Online

  • Home
  • Producers online

Latest Post

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … Coherent Launches Best-In-Class 18 W 880 nm Single-Emitter Laser Diode For High-Performance DPSS Systems
Producers

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

June 15, 2025 admin
Producers

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

June 15, 2025 admin
Producers

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

June 15, 2025 admin
Producers

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

June 15, 2025 admin
Producers

Coherent Launches Best-In-Class 18 W 880 nm Single-Emitter Laser Diode For High-Performance DPSS Systems

June 15, 2025 admin
  • Latest
  • Popular
  • Trending
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Producers
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
Producers
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Producers
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Communiqué :  Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
Producers
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
Brazil upholds 18% tariff on US ethanol imports
Producers
Brazil upholds 18% tariff on US ethanol imports
AACC rebrands itself
Producers
AACC rebrands itself
Vital role of food, agriculture explored in ABA study
Producers
Vital role of food, agriculture explored in ABA study
Wheat Quality Council highlights sustainability, regulation, nutrition
Producers
Wheat Quality Council highlights sustainability, regulation, nutrition
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Producers
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
Producers
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Producers
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Communiqué :  Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
Producers
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
Producers

ASA adds leadership to policy communications team

August 20, 2024 admin

ASA adds leadership to policy communications team | World-grain.com | May 30, 2018 13:09 | World Grain Skip To Content Source

Producers

AFIA announces $170,000 in federal funding

August 20, 2024 admin

AFIA announces $170,000 in federal funding | World Grain Skip To Content Source

Producers

US commodity groups receive funding to build export markets

August 20, 2024 admin

US commodity groups receive funding to build export markets | World Grain Skip To Content Source

Producers

AIB updates Nutrified Labels database

August 19, 2024 admin

AIB updates Nutrified Labels database | World-grain.com | March 01, 2017 14:17 | World Grain Skip To Content Source

Producers

KSU hires coordinator for global food systems initiative

August 19, 2024 admin

KSU hires coordinator for global food systems initiative | World-grain.com | April 27, 2017 14:37 | World Grain Skip To Content Source

Producers

AFIA course covers animal food safety

August 19, 2024 admin

AFIA course covers animal food safety | World Grain Skip To Content Source

Producers

U.S. groups prefer long-term solution over aid package

August 19, 2024 admin

U.S. groups prefer long-term solution over aid package | World-grain.com | July 25, 2018 15:01 | World Grain Skip To Content Source

Producers

IPPE report: MFA plant wins Feed Mill of the Year

August 19, 2024 admin

IPPE report: MFA plant wins Feed Mill of the Year | World Grain Skip To Content Source

Producers

Feed industry must build own ESG journey

August 19, 2024 admin

Feed industry must build own ESG journey | World Grain Skip To Content Source

Producers

Report highlights strength of Canadian agriculture

August 19, 2024 admin

Report highlights strength of Canadian agriculture | World-grain.com | April 16, 2014 09:47 | World Grain Skip To Content Source

Posts pagination

1 … 365 366 367 … 379

Recent Posts

  • Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
  • Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
  • Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
  • Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
  • Coherent Launches Best-In-Class 18 W 880 nm Single-Emitter Laser Diode For High-Performance DPSS Systems

Producers Online
Producers Online

No comments to show.

Archives

  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • November 2024
  • October 2024
  • September 2024
  • August 2024

Categories

  • Producers
  • Българо-китайска търговско-промишлена палата

You missed

Producers

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

June 15, 2025 admin
Producers

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

June 15, 2025 admin
Producers

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

June 15, 2025 admin
Producers

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

June 15, 2025 admin

Producers Online

Producers Online

Proudly powered by WordPress | Theme: Newsup by Themeansar.

  • Home
  • Producers online